Table 1. The Dubai MIST cohort.
MIST, minimally invasive surfactant therapy; LISA, less invasive surfactant therapy; nCPAP, nasal continuous positive airway pressure; ETT, endotracheal tube; ROP, retinopathy of prematurity.
| Serial no | Gestation (weeks) | Birth weight (kg) | Sex | Age @ MIST (hours) | Surfactant preparation | Need for escalation of support, end of oxygen treatment, or total duration of oxygen days | Outcome, age at last assessment, ROP status |
| 1. | 30+6 | 1.03 | Male | 16 | Survanta (feeding tube) | No, nCPAP x 28 h post MIST | Intact survival, 2 years, No ROP |
| 2. | 35+3 | 2.115 | Male | 5 | Curosurf (feeding tube) | No, nCPAP X 2 days post MIST | Intact survival, 2 years, No ROP |
| 3. | 28+1 | 1.18 | Female | 9 | Curosurf (feeding tube) | Yes, HFO, PPHN, Pneumothoraces, repeat survanta on day 7 by ETT, total of 15 oxygen days | Survived. 2 years, Laser for ROP III x once |
| 4. | 32+1 | 1.75 | Male | 6 | Survanta (feeding tube) | No, nCPAP x 24 h post MIST | Intact survival, 2 years, No ROP |
| 5. | 34 | 2.4 | Male | 12.5 | Curosurf (feeding tube) | No, nCPAP x 2 days post MIST | Intact survival, 2 years, No ROP |
| 6. | 27+5 | 0.95 | Female | 14 | Curosurf (feeding tube) | No, nCPAP x 3 days post MIST | Intact survival, 2 years, No ROP |
| 7. | 33 | 2.0 | Male Twin 2 | 21 | Curosurf (LISA catheter) | No, nCPAP x 13 h post MIST to room air | Intact survival, 2 years, No ROP |
| 8. | 33 | 2.1 | Male Twin 1 | 44 (self pay issues) | Curosurf (feeding tube) | No, nCPAP x 33 h post MIST to room air | Intact survival, 2 years, No ROP |
| 9. | 34 | 2.81 | Female | 13 | Survanta (2 size ETT syringe attached direct removing the adapter) | Intact survival, 18 months, No ROP | |
| 10. | 34 (2nd dose in same baby) | 2.81 | Female | 22 | Survanta 2nd dose (same technique as above) | No, nCPAP continued for 1 day post 2nd MIST, Off O2 3 days post 2nd MIST | |
| 11 | 36+2 | 2.37 | Female | 40 h 45 | Curosurf 6 mL (feeding tube) | No, off nCPAP 8 h post MIST, off Oxygen 4 days post MIST | Intact survival, 15 months, no ROP |
| 12 | 32+2 | 2.24 | Female | 12 | Curosurf 6 mL (feeding tube) | No, 20 h post MIST weaned off CPAP and O2 | Survival, 12 months, no ROP |
| 13 | 29+3 | 1.39 | Male | 4 h | Survanta 8 mL By 2.0 ETT | No diagnosed as having single ventricle morphology CCHD as baby did not improve even after two doses of Survanta by MIST. Referred to cardiac center | Survival, 9 months, no ROP |
| 14 | 29+3 (same baby as in 13) | Same | Male | 10 h | Survanta 8 mL By 2.0 ETT | ||
| 15 | 32+3 | 1.93 | Female | 12 h | Curosurf 480 mg | No, 9 h post MIST weaned off CPAP and O2 stopped at 24 h age | Intact survival, 3 months, no ROP |